This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by van Vollenhoven, R F Articles by McGuire, J L Search for Related Content PubMed PubMed Citation Articles by van Vollenhoven, R F Articles by McGuire, J L Social Bookmarking                         What's this?

A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus

Division of Immunology & Rheumatology, Stanford, University Medical Center; Department of Rheumatology, Karolinska Hospital, Stockholm, 17176 Sweden ronaldv{at}rheum.ks.se

J L Park

M C Genovese

J P West

Division of Immunology & Rheumatology, Stanford, University Medical Center

J L McGuire

Objective: To determine if dehydroepiandrosterone (DHEA) is beneficial in severe systemic lupus erythematosus (SLE).

Methods: A double-blinded, placebo-controlled, randomized clinical trial in 21 patients with severe and active SLE, manifestated primarily by nephritis, serositis or hematological abnormalities. In addition to conventional treatment with corticosteroids +/-immunosuppressives, patients received DHEA 200 mg/d vs placebo for 6 months, followed by a 6-month open label period. The primary outcome was a prospectively defined responder analysis, based on a quantitatively specified improvement of the principal severe lupus manifestation at 6 months.

Results: Nineteen patients were available for evaluation at 6 months. Baseline imbalance between the groups was noted, with the DHEA group having greater disease activity at baseline (P < 0.05 by physician's global assessment). Eleven patients were responders: 7/9 patients on DHEA vs 4=10 patients on placebo (P < 0.10). Of the secondary outcomes, mean improvement in SLE disease activity index (SLE-DAI) score was greater in the DHEA group (710.3 3.1 vs 73.9 1.4, P < 0.07). Bone mineral density at the lumbo-sacral spine showed significant reduction in the placebo group, but was maintained in the DHEA group.

Conclusion: DHEA therapy, when added to conventional treatment for severe SLE, may at most have a small added benefit with respect to lupus outcomes, but baseline imbalances in the study population limit the generalizability of the results. DHEA appears to have a protective effect with respect to corticosteroid-induced osteopenia in such patients.

Key Words: SLE • DHEA • treatment

Lupus, Vol. 8, No. 3, 181-187 (1999)
DOI: 10.1191/096120399678847588


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G K Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints Ann Rheum Dis, April 1, 2009; 68(4): 477 - 483. [Abstract] [Full Text] [PDF]

				S. Y. Yuen and J. E. Pope Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials Rheumatology, September 1, 2008; 47(9): 1367 - 1372. [Abstract] [Full Text] [PDF]

				M D Koller, E Templ, M Riedl, M Clodi, O Wagner, J S Smolen, and A Luger Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus Ann Rheum Dis, December 1, 2004; 63(12): 1677 - 1680. [Abstract] [Full Text] [PDF]

				F. Labrie, V. Luu-The, C. Labrie, A. Belanger, J. Simard, S.-X. Lin, and G. Pelletier Endocrine and Intracrine Sources of Androgens in Women: Inhibition of Breast Cancer and Other Roles of Androgens and Their Precursor Dehydroepiandrosterone Endocr. Rev., April 1, 2003; 24(2): 152 - 182. [Abstract] [Full Text] [PDF]

				W. Arlt, F. Callies, I. Koehler, J. C. van Vlijmen, M. Fassnacht, C. J. Strasburger, M. J. Seibel, D. Huebler, M. Ernst, M. Oettel, et al. Dehydroepiandrosterone Supplementation in Healthy Men with an Age-Related Decline of Dehydroepiandrosterone Secretion J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4686 - 4692. [Abstract] [Full Text] [PDF]

				S. S. C. Yen Dehydroepiandrosterone sulfate and longevity: New clues for an old friend PNAS, July 17, 2001; 98(15): 8167 - 8169. [Full Text] [PDF]

				R. F. van Vollenhoven Dehydroepiandrosterone in the treatment of systemic lupus erythematosus Rheumatology, August 1, 2000; 39(8): 929 - 930. [Full Text] [PDF]

				D. Isenberg and R. Ramsey-Goldman Assessing patients with lupus: towards a drug responder index Rheumatology, November 1, 1999; 38(11): 1045 - 1049. [Full Text] [PDF]

				R. Ramsey-Goldman and K. W Hayes Ensuring reliability of clinical assessments for SLE trials Lupus, October 1, 1999; 8(8): 671 - 676. [Abstract] [PDF]

				R. G Lahita Dehydroepiandrosterone (DHEA) for serious disease, a possibility? Lupus, March 1, 1999; 8(3): 169 - 170. [PDF]